In a report issued on June 24, Marie Thibault from BTIG maintained a Buy rating on Atricure (ATRC – Research Report), with a price target of $75.00. The company's shares closed last Friday at $40.92, close to its 52-week low of $32.84. According to TipRanks.com, Thibault is a 4-star analyst with an average return of 6.2% and a 27.2% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies. Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $72.33, which is an 85.1% upside from current levels.
https://www.tipranks.com/news/blurbs/btig-keeps-a-buy-rating-on-atricure-atrc?utm_source=advfn.com&utm_medium=referral
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more AtriCure Charts.
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more AtriCure Charts.